Market Intelligence, Clinical Progress, and High-Purity Reagents for Anemia, Oncology, and Hematological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EPOR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPOR ECD-Fc Fusion Protein Human extracellular domain (Met1-Pro250), HEK293 expressed, High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View EPOR Products |
| Gene Delivery | EPOR Lentivirus Premade Particles Full-length ORF with puromycin selection marker. For stable EPOR+ cell line construction. |
View EPOR Products |
| Benchmark Ab | Anti-EPOR (Sequence of Benchmark Antibody) Recombinant positive control for binding and neutralization assays. |
View EPOR Products |
| Validator | EPOR siRNA Set (3 unique targets) For knockdown verification and specificity controls in signaling assays. |
View EPOR Products |
| Related Target: EPO | Erythropoietin (EPO) Natural ligand. Critical for competitive binding and dimerization assays. |
View EPO Products |
| Related Target: JAK2 | JAK2 (Wild-type & V617F Mutant) Downstream signaling validation and resistance mechanism studies. |
View JAK2 Products |
| Related Target: TPOR/MPL | Thrombopoietin Receptor (MPL) Off-target liability screening; shares JAK2 signaling pathway. |
View MPL Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation Dependency | HEK293-expressed EPOR ensures correct post-translational modifications essential for proper folding and ligand binding. |
| Receptor Dimerization Disruption | EPOR ECD-Fc preserves native dimerization interface; validated by SPR for pre-formed complex inhibition. |
| Cross-Reactivity with TPOR (MPL) | Human/Mouse/Cyno ortholog proteins available with >95% purity; strict sequence homology verification. |
| JAK2/STAT5 Pathway Validation | Lentivirus-transduced BaF3 cells for functional signaling assays; Endotoxin controlled (<0.1 EU/µg) to prevent false positives. |
| Internalization Kinetics (ADC Development) | HEK293-expressed full-length EPOR lentivirus for stable cell line generation; preserves native glycosylation and conformation. |
| Lack of Controls | Clinical Benchmark EPO proteins and anti-EPOR reference antibodies included as assay standards. |
| False Positives | Validated siRNA included for specificity checks; mutant JAK2 V617F for resistance mechanism studies. |
Live EPOR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The EPOR-targeting therapeutic landscape is undergoing significant transformation. First-generation erythropoiesis-stimulating agents (ESAs) face patent expirations and biosimilar competition, while major players continue to refine long-acting ESAs. Simultaneously, the field is shifting toward alternative mechanisms like HIF-PH inhibitors that indirectly modulate EPOR signaling through endogenous EPO upregulation. The next wave of R&D emphasizes biased signaling to maximize red blood cell production while minimizing cardiovascular and thrombotic risks, receptor selectivity (avoiding TPOR cross-talk), improved pharmacokinetics for subcutaneous delivery, and combination strategies with iron metabolism modulators. Personalized anemia management in chronic kidney disease (CKD) and myelodysplastic syndromes (MDS) is a key strategic focus.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant EPO (Biosimilar) | Amgen, Roche, Pfizer | CKD Anemia, Chemotherapy-induced Anemia | Receptor Binding Affinity (Need high-purity EPOR ECD-Fc for SPR/BLI) |
| HIF-PH Inhibitors | Fibrogen/AstraZeneca, GSK | Anemia of CKD | Endogenous EPO Level Detection (Need EPOR protein for sandwich ELISA development) |
| Small Molecule Agonists | Various biotechs | Hereditary Hemochromatosis, Beta-thalassemia | Dimerization Assay (Need EPOR extracellular domain for FRET/BRET studies) |
| Anti-EPOR ADCs | Emerging biotechs | EPOR+ Solid Tumors (investigational) | Internalization Assay (Need full-length EPOR lentivirus for stable cell lines) |
| Peptide Mimetics | Affymax (historical), new entrants | Anemia (short-acting) | Cross-species Activity (Need Cyno/Mouse EPOR proteins for toxicology bridging) |
| Gene Therapy | Various biotechs | Beta-Thalassemia | Expression validation (Need Sequence Verified ORFs) |